-+ 0.00%
-+ 0.00%
-+ 0.00%

SENTI BIO ANNOUNCES FIRST PATIENT DOSED IN CLINICAL TRIAL OF SN301A IN HEPATOCELLULAR CARCINOMA IN COLLABORATION WITH CELEST THERAPEUTICS

Reuters·12/16/2024 13:00:03

Please log in to view news